CA2906689A1 - Meropenem derivatives and uses thereof - Google Patents

Meropenem derivatives and uses thereof Download PDF

Info

Publication number
CA2906689A1
CA2906689A1 CA2906689A CA2906689A CA2906689A1 CA 2906689 A1 CA2906689 A1 CA 2906689A1 CA 2906689 A CA2906689 A CA 2906689A CA 2906689 A CA2906689 A CA 2906689A CA 2906689 A1 CA2906689 A1 CA 2906689A1
Authority
CA
Canada
Prior art keywords
compound
certain embodiments
kda
pharmaceutical composition
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906689A
Other languages
English (en)
French (fr)
Inventor
Winston Zapanta ONG
Pawel Wojciech Nowak
Jinsoo Kim
Elizabeth M. Enlow
James BOURASSA
Yen CU
Alexey Popov
Hongming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of CA2906689A1 publication Critical patent/CA2906689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2906689A 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof Abandoned CA2906689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789335P 2013-03-15 2013-03-15
US61/789,335 2013-03-15
PCT/US2014/028627 WO2014144285A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CA2906689A1 true CA2906689A1 (en) 2014-09-18

Family

ID=51537664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906689A Abandoned CA2906689A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Country Status (8)

Country Link
US (4) US9725451B2 (https=)
EP (1) EP2968274B1 (https=)
JP (2) JP2016517435A (https=)
AU (2) AU2014227737B2 (https=)
BR (1) BR112015023621A8 (https=)
CA (1) CA2906689A1 (https=)
HK (1) HK1219233A1 (https=)
WO (1) WO2014144285A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362239B (zh) * 2020-03-20 2021-07-06 辽宁瑞鸥新材料科技有限公司 一种用于铝硅系合金半固态制浆的Cs2HPO4气溶胶及其使用方法
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3216616A1 (en) * 2021-04-27 2022-11-03 Philip V. Felice Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZM884A1 (en) * 1983-01-28 1984-10-22 Bristol Myers Co Substituted vinyl cephalosporins
EP0130119B1 (en) * 1983-06-23 1988-11-09 Merck & Co. Inc. (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4914091A (en) 1984-04-02 1990-04-03 American Cyanamid Company Esters of cephalosporin derivitives
JPS6247874A (ja) 1985-08-27 1987-03-02 Sankyo Seiki Mfg Co Ltd プログラム動作装置の初期化方法
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
TR200003199T2 (tr) 1998-05-01 2001-03-21 Kyoto Pharmaceutical Industries, Ltd. Karbapenem türevleri, bunların kullanımı ve ara birleşiği
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
JP2000344772A (ja) 1998-05-01 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、その用途およびその中間体化合物
JP2000344774A (ja) * 1999-06-03 2000-12-12 Meiji Seika Kaisha Ltd カルバペネム類の製造法
KR20040000466A (ko) * 2001-05-21 2004-01-03 교토 야쿠힝 고교 가부시키가이샤 카르바페넴 화합물
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
PH12013500954A1 (en) * 2010-11-11 2017-05-19 Redx Pharma Plc Drug derivatives
NZ722096A (en) * 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport

Also Published As

Publication number Publication date
AU2018203005A1 (en) 2018-05-17
US20160039823A1 (en) 2016-02-11
US20170349590A1 (en) 2017-12-07
US20210332048A1 (en) 2021-10-28
EP2968274A1 (en) 2016-01-20
US11091487B2 (en) 2021-08-17
HK1219233A1 (zh) 2017-03-31
BR112015023621A8 (pt) 2018-01-23
EP2968274B1 (en) 2019-10-16
WO2014144285A1 (en) 2014-09-18
BR112015023621A2 (pt) 2017-07-18
US10392388B2 (en) 2019-08-27
AU2014227737B2 (en) 2018-05-17
US20200010470A1 (en) 2020-01-09
EP2968274A4 (en) 2016-08-24
JP2016517435A (ja) 2016-06-16
US9725451B2 (en) 2017-08-08
AU2014227737A1 (en) 2015-10-08
JP2019089829A (ja) 2019-06-13
JP6738918B2 (ja) 2020-08-12

Similar Documents

Publication Publication Date Title
US20210332048A1 (en) Meropenem derivatives and uses thereof
AU2014214547B2 (en) Methods of treating topical microbial infections
AU2014342042B2 (en) Crystalline forms of therapeutic compounds and uses thereof
US20130316001A1 (en) Particles, compositions and methods for ophthalmic and/or other applications
CN108135967A (zh) 用于药物递送的具有渗透增强剂的组合物
US12502433B2 (en) Phosphonate-drug conjugates
TW201444559A (zh) 與類固醇藥物連接之抗生素結合物
CA3116889A1 (en) Organosilanes for the treatment of infections
JP6426195B2 (ja) 治療用化合物の結晶形態及びその使用
JP2023041861A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
US20170260193A1 (en) Crystalline Forms of Therapeutic Compounds and Uses Thereof
HK1228197B (en) Crystalline forms of therapeutic compounds and uses thereof
HK1228197A1 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190314

FZDE Discontinued

Effective date: 20230516